Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the world. With the deepening understanding of NAFLD, more and more evidence has shown that NAFLD is a group of highly heterogeneous diseases, which is closely related to metabolic dysfunction. Recent studies have shown that the occurrence of nonalcoholic fatty liver disease is closely related to the dysbiosis of intestinal flora. However, due to the abuse of antibiotics, long-term use of broad-spectrum antibiotics is the most common cause of intestinal flora disorders. Endocrine and metabolic disorders caused by intestinal microbiota imbalance promote the occurrence of obesity, and on this basis induce the emergence of NAFLD. In response to the current situation of antibiotic resisftance pandemic, phage therapy has emerged as a potential solution to solve the problem of bacterial resistance. Relevant clinical studies have shown that fecal bacterial transplantation (FMT) can improve the clinical symptoms of patients with chronic liver disease, in which phage participate in the regulating effect. This suggests that phages may play a role in the treatment of non-alcoholic fatty liver disease caused by antibiotic resistance, but there is insufficient clinical evidence to support this therapy. Therefore, this review will discuss the mechanism of non-alcoholic fatty liver disease caused by antibiotics resistance and evaluate the therapeutic effect of bacteriophages.